The frequency of CTX-M gene in Enterobacteriaceae ESBL of hospital origin

A total of 37 clinical isolates of enterobacteriaceaes (16 Escherichia coli, 10 Klebsiella pn., 7 Enterobacter Cloacae, 2 Morganella Morganii, 1 Proteus Mirabilis and 1 Citrobacter Freundi ) were recovered during 2014 from four Moroccan regions to study their resistance profile. Among these 37 strai...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of innovation and applied studies 2016-04, Vol.15 (2), p.240-240
Hauptverfasser: Sahraoui, Hajar Lahdibi, Berny, El Hassan, Quasmaoui, Aicha, Charof, Reda, Mennane, Zakaria
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A total of 37 clinical isolates of enterobacteriaceaes (16 Escherichia coli, 10 Klebsiella pn., 7 Enterobacter Cloacae, 2 Morganella Morganii, 1 Proteus Mirabilis and 1 Citrobacter Freundi ) were recovered during 2014 from four Moroccan regions to study their resistance profile. Among these 37 strains, 19 tell ESBL Enterobacteriaceae. Over this period, the bacterial species most often ESBL producing was Escherichia coli (9 strains), followed by Klebsiella pneumoniae (7 strains), Enterobacter cloacae (2 strains), and Morganella Morganii (1 strains). The ESBL resistance was screened using disc diffusion method, while the resistance genes were detected by polymerase chain reaction (PCR). The results marked the high prevalence of gene CTX-M (16 strains). This study points out the high rate of transmission of CTX-M gene among Escherichia coli,Klebsiella pneumonia, Enterobacter cloacae strains and shows a reduced sensitivity to Penicillins (Amoxicillin-clavulanic acid, Amoxicillin, and Ticarcillin (0%)), to Cepholosporins 3 rdgeneration Cefotaxim ( 7,7%), Ceftazidim (11,5%), and to Fluoroquinolones (Ciprofloxacin, Norfloxacin, and nalidixic acid (3,8%). In addition, all tested strains were highly susceptible to imipenem (96,2%) and Trimethoprim-sulfamethoxazole (73,1%).
ISSN:2028-9324
2028-9324